ASHLEY HUITT: Open Payments
NPI 1104462712 · WARREN, AR. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$487 in 23 payments from 10 companies in 2025. Trend: 2023 $308 · 2024 $263 · 2025 $487
Food & beverage: $487
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | 5 | $149 |
| ABBVIE INC. | 7 | $137 |
| Novo Nordisk Inc | 3 | $55 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 2 | $41 |
| Otsuka America Pharmaceutical, Inc. | 1 | $23 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 1 | $21 |
| Amgen Inc. | 1 | $19 |
| Exact Sciences Corporation | 1 | $16 |
| Lilly USA, LLC | 1 | $15 |
| Axsome Therapeutics, Inc. | 1 | $11 |
Products named: QULIPTA, AIRSUPRA, VRAYLAR, FARXIGA, JARDIANCE, Ozempic, BREZTRI, REXULTI.
Industry payments across AR — which companies pay providers there.
